Immune Technologies and Medicine

Immune Technologies and Medicine (ITM) is a biotechnology company focused on the development of next-generation T-cell receptor (TCR) therapies for the treatment of cancer and infectious diseases. The company leverages a proprietary platform to identify and engineer high-affinity TCRs that can specifically target tumor-associated antigens or viral proteins. By optimizing the interaction between T cells and their targets, ITM aims to overcome the limitations of current immunotherapies, particularly in the context of solid tumors. Their approach combines advanced bioinformatics with high-throughput screening to accelerate the discovery of therapeutic candidates.